5 research outputs found
Poor clinical outcomes for HIV infected children on antiretroviral therapy in rural Mozambique: need for program quality improvement and community engagement.
Residents of Zambézia Province, Mozambique live from rural subsistence farming and fishing. The 2009 provincial HIV prevalence for adults 15-49 years was 12.6%, higher among women (15.3%) than men (8.9%). We reviewed clinical data to assess outcomes for HIV-infected children on combination antiretroviral therapy (cART) in a highly resource-limited setting.We studied rates of 2-year mortality and loss to follow-up (LTFU) for children <15 years of age initiating cART between June 2006-July 2011 in 10 rural districts. National guidelines define LTFU as >60 days following last-scheduled medication pickup. Kaplan-Meier estimates to compute mortality assumed non-informative censoring. Cumulative LTFU incidence calculations treated death as a competing risk.Of 753 children, 29.0% (95% CI: 24.5, 33.2) were confirmed dead by 2 years and 39.0% (95% CI: 34.8, 42.9) were LTFU with unknown clinical outcomes. The cohort mortality rate was 8.4% (95% CI: 6.3, 10.4) after 90 days on cART and 19.2% (95% CI: 16.0, 22.3) after 365 days. Higher hemoglobin at cART initiation was associated with being alive and on cART at 2 years (alive: 9.3 g/dL vs. dead or LTFU: 8.3-8.4 g/dL, p<0.01). Cotrimoxazole use within 90 days of ART initiation was associated with improved 2-year outcomes Treatment was initiated late (WHO stage III/IV) among 48% of the children with WHO stage recorded in their records. Marked heterogeneity in outcomes by district was noted (p<0.001).We found poor clinical and programmatic outcomes among children taking cART in rural Mozambique. Expanded testing, early infant diagnosis, counseling/support services, case finding, and outreach are insufficiently implemented. Our quality improvement efforts seek to better link pregnancy and HIV services, expand coverage and timeliness of infant diagnosis and treatment, and increase follow-up and adherence
Variation by district in pediatric loss to follow up (LTFU), death, and death or LTFU for 2 years following combination antiretroviral therapy initiation, 10 districts of Zambézia Province, Mozambique, 2006–2011.
<p>Variation by district in pediatric loss to follow up (LTFU), death, and death or LTFU for 2 years following combination antiretroviral therapy initiation, 10 districts of Zambézia Province, Mozambique, 2006–2011.</p
Characteristics of children at initiation of combination antiretroviral therapy by 2 year outcome in 10 districts of Zambézia Province, Mozambique, 2006–2011 (PITC = Provider-initiated testing and counseling; PMTCT = Prevention of mother-to-child HIV transmission; BMI = Body Mass Index or weight in kg divided by height squared).
<p>Percentages are computed using the number of patients with a non-missing value.</p>1<p>Weight, height, and BMI are collected at enrollment. <sup>2</sup>Collected within 90 days before and 14 days after ART initiation. <sup>3</sup>Prior to ART means any cotrimoxazole (CTX) use recorded in 365 days prior to ART initiation. Current means any CTX use in 90 days before or 90 days after ART initiation. CTX use is recorded along with the visit date; data is not collected on non-users so we are unable to assess missing data. <sup>4</sup>When PITC referral sites are grouped: p = 0.9.</p><p>Characteristics of children at initiation of combination antiretroviral therapy by 2 year outcome in 10 districts of Zambézia Province, Mozambique, 2006–2011 (PITC = Provider-initiated testing and counseling; PMTCT = Prevention of mother-to-child HIV transmission; BMI = Body Mass Index or weight in kg divided by height squared).</p